NO20015015L - Östrogenreseptor-<beta>-ligander - Google Patents

Östrogenreseptor-<beta>-ligander

Info

Publication number
NO20015015L
NO20015015L NO20015015A NO20015015A NO20015015L NO 20015015 L NO20015015 L NO 20015015L NO 20015015 A NO20015015 A NO 20015015A NO 20015015 A NO20015015 A NO 20015015A NO 20015015 L NO20015015 L NO 20015015L
Authority
NO
Norway
Prior art keywords
östrogenreseptor
ligands
beta
Prior art date
Application number
NO20015015A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015015D0 (no
Inventor
Bernard Christophe Barlaam
Timothy Martin Piser
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20015015D0 publication Critical patent/NO20015015D0/no
Publication of NO20015015L publication Critical patent/NO20015015L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20015015A 1999-04-16 2001-10-15 Östrogenreseptor-<beta>-ligander NO20015015L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12990199P 1999-04-16 1999-04-16
PCT/GB2000/001380 WO2000062765A2 (en) 1999-04-16 2000-04-11 ESTROGEN RECEPTOR-β LIGANDS

Publications (2)

Publication Number Publication Date
NO20015015D0 NO20015015D0 (no) 2001-10-15
NO20015015L true NO20015015L (no) 2001-12-17

Family

ID=22442124

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015015A NO20015015L (no) 1999-04-16 2001-10-15 Östrogenreseptor-<beta>-ligander

Country Status (22)

Country Link
US (1) US6518301B1 (is)
EP (1) EP1173164A2 (is)
JP (1) JP2002542187A (is)
KR (1) KR20010108509A (is)
CN (1) CN1358091A (is)
AR (1) AR043085A1 (is)
AU (1) AU4128800A (is)
BG (1) BG106103A (is)
BR (1) BR0009814A (is)
CA (1) CA2370126A1 (is)
CZ (1) CZ20013714A3 (is)
EE (1) EE200100526A (is)
HU (1) HUP0200740A3 (is)
IL (1) IL145839A0 (is)
IS (1) IS6108A (is)
MX (1) MXPA01010423A (is)
NO (1) NO20015015L (is)
PL (1) PL351314A1 (is)
SK (1) SK14762001A3 (is)
TR (2) TR200201762T2 (is)
WO (1) WO2000062765A2 (is)
ZA (1) ZA200108409B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AU2001296119A1 (en) * 2000-10-13 2002-04-22 Astrazeneca Ab Estrogen receptor-beta ligands
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
AU2002221239A1 (en) * 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
JP2004515494A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ 治療剤
US6559177B2 (en) 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
ATE362471T1 (de) 2001-11-19 2007-06-15 Lilly Co Eli Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7235539B2 (en) 2002-01-23 2007-06-26 Wyeth 6-Hydroxyequilenins as estrogenic agents
AU2003212856A1 (en) * 2002-03-01 2003-09-16 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1545206B1 (en) 2002-07-24 2020-03-04 Children's Hospital Medical Center Compositions and products containing enantiomeric equol, and methods for their making
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US8668914B2 (en) * 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US20050245492A1 (en) * 2004-04-28 2005-11-03 Lephart Edwin D Use of equol for treating skin diseases
WO2004014886A1 (en) * 2002-08-07 2004-02-19 University Of Mississippi Antigiardial agents and use thereof
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
CN100374444C (zh) 2003-04-21 2008-03-12 伊莱利利公司 作为选择性β-雌激素受体激动剂的取代的苯并吡喃化合物
US20060046968A1 (en) * 2004-08-26 2006-03-02 Wyeth Prodrug substituted benzoxazoles as estrogenic agents
KR20070061536A (ko) 2004-09-07 2007-06-13 와이어쓰 ６Ｈ-[１]벤조피라노[４,３-ｂ]퀴놀린 및 에스트로겐제제로서의 이의 용도
TW200637545A (en) * 2004-12-17 2006-11-01 Wyeth Corp Novel uses for estrogen beta agonists
US8093302B2 (en) * 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
JP2008533177A (ja) * 2005-03-24 2008-08-21 ノボジェン リサーチ ピーティーワイ リミテッド 抗炎症治療法
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
MX2008006885A (es) * 2005-11-28 2008-10-20 Gtx Inc Agentes de enlace de receptores nucleares.
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
JP5819196B2 (ja) * 2008-10-29 2015-11-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 液晶ディスプレイ
TWI472525B (zh) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
ES2343347B2 (es) * 2009-01-27 2011-12-07 Universidade De Santiago De Compostela Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados.
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CN101863867B (zh) * 2009-04-14 2012-07-18 清华大学深圳研究生院 黄酮类化合物的衍生物及其制备方法与应用
US10292994B2 (en) 2011-04-25 2019-05-21 Council Of Scientific & Industrial Research Bioactive fractions and compounds from Dalbergia sissoo for the prevention or treatment of osteo-health related disorders
CN103450134B (zh) * 2012-05-31 2017-12-22 中国医学科学院药物研究所 香豆素衍生物的制备及其在防治脑部重大疾病中的应用
US9718799B2 (en) * 2015-05-11 2017-08-01 University Of Kentucky Research Foundation 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer
EP3597187A1 (en) * 2018-07-16 2020-01-22 Centre National De La Recherche Scientifique Brag2 inhibitors and applications thereof
CN112574177B (zh) * 2020-12-21 2023-01-31 陕西师范大学 一类嘧啶衍生物及其制备抗肿瘤药物的应用
CN115322198A (zh) * 2022-06-13 2022-11-11 上海工程技术大学 基于喹诺里西啶类衍生物的药物化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954371A (is) * 1972-09-28 1974-05-27
GB1495189A (en) * 1975-09-12 1977-12-14 Pfizer Ltd 4-oxo-4h-benzopyran derivatives and process for their preparation
JPS6048924A (ja) * 1983-08-24 1985-03-16 Takeda Chem Ind Ltd 骨粗鬆症治療剤
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
JP3085464B2 (ja) * 1990-05-24 2000-09-11 コニカ株式会社 感熱拡散転写材料
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
JPH05112552A (ja) * 1991-10-17 1993-05-07 Tanabe Seiyaku Co Ltd ベンゾピラン誘導体及びその製法
JP3166093B2 (ja) * 1993-08-13 2001-05-14 森永乳業株式会社 クマリン誘導体及びそれらの用途
JPH06321752A (ja) * 1993-05-07 1994-11-22 Kao Corp 美白剤
JP3522754B2 (ja) * 1993-12-16 2004-04-26 マリンクロッド・インコーポレイテッド 多価フェノール化合物類
US5998401A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
GB9707013D0 (en) 1997-04-07 1997-05-28 Univ Strathclyde Halo and/or nitro-substituted flavonoids
NZ527735A (en) * 1997-05-01 2005-10-28 Novogen Inc Treatment or prevention of menopausal symptoms and osteoporosis

Also Published As

Publication number Publication date
TR200102992T2 (tr) 2004-12-21
HUP0200740A3 (en) 2004-08-30
IL145839A0 (en) 2002-07-25
US6518301B1 (en) 2003-02-11
NO20015015D0 (no) 2001-10-15
CZ20013714A3 (cs) 2002-08-14
AU4128800A (en) 2000-11-02
PL351314A1 (en) 2003-04-07
KR20010108509A (ko) 2001-12-07
SK14762001A3 (sk) 2002-10-08
MXPA01010423A (es) 2002-03-27
WO2000062765A2 (en) 2000-10-26
BG106103A (en) 2002-05-31
AR043085A1 (es) 2005-07-20
TR200201762T2 (tr) 2002-10-21
WO2000062765A3 (en) 2001-09-07
HUP0200740A2 (hu) 2002-07-29
EE200100526A (et) 2002-12-16
JP2002542187A (ja) 2002-12-10
EP1173164A2 (en) 2002-01-23
BR0009814A (pt) 2002-01-08
CA2370126A1 (en) 2000-10-26
CN1358091A (zh) 2002-07-10
IS6108A (is) 2001-10-15
ZA200108409B (en) 2003-03-26

Similar Documents

Publication Publication Date Title
NO20015015L (no) Östrogenreseptor-&lt;beta&gt;-ligander
NO20006268D0 (no) &lt;Beta&gt;karbolinforbindelser
IS6024A (is) Ný efnasambönd
EE200200033A (et) Uued ühendid
DE10084662T1 (de) Mehrfachbahn-Verbinden
ATA51899A (de) Handstempel
DE50002558D1 (de) Rückspülfiltervorrichtung
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
IS6139A (is) Ný efnasambönd
NO20014010D0 (no) &lt;beta&gt;-alaninderivater
NO20013769D0 (no) Kalsilytiske forbindelser
NO20020466L (no) Kalsilytiske forbindelser
IS6141A (is) Ný efnasambönd
NO20014262D0 (no) Tiazoloindolinon-forbindelser
FI19991874A (fi) Laskutus
ATE269311T1 (de) Benzoylpyridazine
DE10082008D2 (de) Ausbeulgerät
DE60020365D1 (de) Säurekatalysierte umsetzungen
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
DE29909109U1 (de) Zusammengesetzter Aktenordner
AT500658A3 (de) Isolierplatte
ATA732000A (de) Kachelofen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application